scale average bioequivalence for parallel design [RSABE / ABEL]

posted by Mahmoud  – Jordan, 2022-06-15 14:33 (1038 d 10:40 ago) – Posting: # 23059
Views: 3,230

Dear All
In the following paper

Statistical methodology for highly variable compounds: A novel design approach for the Ofatumumab Phase 2 bioequivalence study

Used scale average bioequivalence for parallel design

Is this method accepted by FDA and EMA

M.Youseef


Edit: Category changed; see also this post #1[Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,707 registered users;
24 visitors (0 registered, 24 guests [including 8 identified bots]).
Forum time: 01:14 CEST (Europe/Vienna)

Do not worry about your difficulties in mathematics.
I can assure you mine are still greater.    Albert Einstein

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5